3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-1-三苯甲游基-吡唑并[5,4-b]吡啶 | 1319591-26-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-1-三苯甲游基-吡唑并[5,4-b]吡啶
• 英文名称: 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tritylpyrazolo[5,4-b]pyridine
• 英文别名: 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-pyrazolo[3,4-b]pyridine；3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tritylpyrazolo[5,4-b]pyridin；3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-1H-pyrazolo[3,4-b]pyridine；3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tritylpyrazolo[3,4-b]pyridine
• CAS: 1319591-26-8
• 化学式: C₃₁H₃₀BN₃O₂
• 分子量: 487.409
• InChiKey: KKYPZKHAVFUVKT-UHFFFAOYSA-N

物化性质

• 沸点：
  646.3±55.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.57
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  49.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-1-三苯甲游基-吡唑并[5,4-b]吡啶 在 四(三苯基膦)钯 、 sodium carbonate 、 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 、 甲醇 、 水 、 甲苯 为溶剂， 反应 7.0h， 生成
  参考文献：
  名称：

  Design and Optimization of Selective Protein Kinase C θ (PKCθ) Inhibitors for the Treatment of Autoimmune Diseases

  摘要：

  Protein kinase C theta (PKC theta) has a central role in T cell activation and survival; however, the dependency of T cell responses to the inhibition of this enzyme appears to be dictated by the nature of the antigen and by the inflammatory environment. Studies in PKC theta-deficient mice have demonstrated that while antiviral responses are PKC theta-independent, T cell responses associated with autoimmune diseases are PKC theta-dependent. Thus, potent and selective inhibition of PKC theta is expected to block autoimmune T cell responses without compromising antiviral immunity. Herein, we describe the development of potent and selective PKC theta inhibitors, which show exceptional potency in cells and in vivo. By use of a structure based rational design approach, a 1000-fold improvement in potency and 76-fold improvement in selectivity over closely related PKC isoforms such as PKC delta were obtained from the initial HTS hit, together with a big improvement in lipophilic efficiency (LiPE).

  DOI：

  10.1021/jm301465a
• 作为产物：
  描述：

  2-氯-3-吡啶甲醛 在 N-溴代丁二酰亚胺(NBS) 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 sodium hydride 、 对甲苯磺酸 、 一水合肼 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 49.0h， 生成 3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-1-三苯甲游基-吡唑并[5,4-b]吡啶
  参考文献：
  名称：

  [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
  [FR] INHIBITEURS DE LA KINASE 7 DÉPENDANTE DES CYCLINES (CDK7)

  摘要：

  公开号：

  WO2018013867A8

文献信息

• [EN] INHIBITORS OF INFLUENZA VIRUSES REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DES VIRUS DE LA GRIPPE
  申请人：VERTEX PHARMA

  公开号：WO2012083117A1

  公开（公告）日：2012-06-21

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制流感病毒在生物样本或患者中复制的方法，减少生物样本或患者中流感病毒的数量，以及治疗患者的流感，包括向所述生物样本或患者投与结构式（I）所代表的化合物的有效量或其药学上可接受的盐，其中结构式（I）的值如本文所述。一种化合物由结构式（I）或其药学上可接受的盐所代表，其中结构式（I）的值如本文所述。一种药物组合物包括这种化合物或其药学上可接受的盐的有效量，以及药学上可接受的载体、辅料或溶剂。
• 杰纳斯激酶抑制剂的合成和应用
  申请人：任婧

  公开号：CN105367587A

  公开（公告）日：2016-03-02

  公开了式(I)化合物，其中R1、R2和Y如式中所定义，该化合物是杰纳斯激酶(JAK)的抑制剂，本身作为免疫抑制剂，可用于器官移植、狼疮、多发性硬化、风湿性关节炎、牛皮癣、I型糖尿病和糖尿病并发症、癌症、哮喘、特应性皮炎、自体免疫性甲状腺机能紊乱、溃疡性结肠炎、局限性回肠炎、阿尔茨海默氏病、白血病和其他自身免疫疾病的治疗。
• [EN] PYRAZOLOPYRIDINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PYRAZOLOPYRIDINE KINASE
  申请人：VERTEX PHARMA

  公开号：WO2011094273A1

  公开（公告）日：2011-08-04

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及作为蛋白激酶抑制剂的化合物。该发明还提供了包括所述化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病、症状或疾病的方法。该发明还提供了制备该发明化合物的方法。
• PYRAZOLOPYRIDINE KINASE INHIBITORS
  申请人：Boyall Dean

  公开号：US20120071494A1

  公开（公告）日：2012-03-22

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及用作蛋白激酶抑制剂的化合物。本发明还提供了包含该化合物的药学上可接受的组合物，并提供了使用该组合物治疗各种疾病、病况或障碍的方法。本发明还提供了制备本发明化合物的方法。
• Inhibitors of influenza viruses replication
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US08871774B2

  公开（公告）日：2014-10-28

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者中流感病毒复制的方法，减少生物样本或患者中流感病毒数量的方法，以及治疗患者流感的方法，包括向该生物样本或患者中给予Structural Formula (I)所代表的化合物的有效量，或其药学上可接受的盐，其中Structural Formula (I)的值如此处所述。化合物由Structural Formula (I)或其药学上可接受的盐所代表，其中Structural Formula (I)的值如此处所述。药物组合物包括有效量的这种化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或载体。